Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? MS ID#: NEURIMMINFL/ 2018/019398

In this study we tested the hypothesis that timing of intravenous (IVMP) affects visual outcome in a cohort of aquaporin4 (AQP4)-IgG and MOG-IgG positive patients with ON by analyzing the effect of the number of days until treatment commenced with the best-corrected visual acuity at three months. The results provides Class III evidence that hyperacute treatment of AQP4 and MOG-ON with IVMP increases the chance for excellent visual recovery (20/20 vision) and that even a greater than 7 day delay in treatment is associated with a higher risk for poor visual recovery.

在本项研究中，我们通过分析治疗开始前所需天数与三个月最佳矫正视力之间的关系，检验了静脉注射（IVMP）时机对AQP4-IgG和MOG-IgG阳性多发性硬化症（ON）患者视觉结果的影响假设。研究结果表明，对AQP4-MOG-ON进行超急性治疗，使用IVMP可显著提高患者实现良好视觉恢复（20/20视力）的可能性，并且治疗延迟超过7天与较差的视觉恢复风险增加相关，提供III级证据。